EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population Authors: Xiao-Rong Yang, Si-Min Zhong, Zhen-Yi Jin, Xīn Gào, Ying Wu, Qing Zhou, Yang-Qiu Li, Si-Yang Maggie Liu, Yi-Long Wu Published: 2024 ABSTRACT AbstractBackgroundEpidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) gene mutations are well established in the pathogenesis of non-small cell lung cancer (NSCLC). However, there is limited understanding about the impact of rare variants, such as EGFR exon 20 insertion mutation (EGFRex20ins) and MET exon 14 skipping mutation (METex14) in the Chinese population even though targeted therapies have been approved in China. We conducted a scoping review to assess the current available evidence of these two mutations in NSCLC in the Chinese population.MethodsElectronic searches were performed before November 2023. Two investigators independently collected data. Any discrepancies were resolved through discussion with a senior investigator.ResultsWe identified 111 studies, involving a total of 159,993 NSCLC Chinese patients. Of the 111 studies, 76 studies reported on EGFRex20ins and 45 reported on METex14. When we evaluated the frequency from studies with at least 1,000 patients, the frequency of EGFRex20ins ranged from 0.02–2.85% of all NSCLC patients and 0.56–6.90% of all EGFR mutations. The frequency of METex14 ranged from 0.08–1.38% of all NSCLC patients and 8.33–56.60% of all MET mutations. The treatments for NSCLC with EGFRex20ins varied depending on the study, and all available treatments have limited therapeutic efficacy and a relatively poor prognosis, and fewer studies have examined the efficacy and effectiveness of treatments for NSCLC with METex14 mutation in the Chinese population.ConclusionsDespite the recent approval of three targeted therapies in China, there is still insufficient evidence regarding their optimal treatment and therapeutic efficacy for Chinese patients. Further large-scale studies are needed to establish links between these mutations and clinical features at baseline and following treatment. Furthermore, moving forward, the development of novel drugs will be essential to fulfill the clinical unmet needs.Keywords: EGFR exon 20 insertion mutation (EGFRex20ins), MET exon 14 skipping mutation (METex14), non-small cell lung cancer (NSCLC), Chinese population Highlight box Key findings • This study provides a comprehensive overview of the prevalence of EGFR exon 20 insertion mutation (EGFRex20ins) and MET exon 14 skipping mutation (METex14) mutations in non-small cell lung cancer (NSCLC) in the Chinese population. • The evidence on the prognostic effect of these mutations was limited to reliably assess the impact on overall survival. • The treatments for NSCLC with EGFRex20ins or METex14 mutation varied depending on the study, and no clear evidence has indicated the optimal treatment regimen during our study period. What is known and what is new? • Some studies have investigated the epidemiological and clinical burden of METex14 in lung cancer in the Chinese population, but there is no systematic summary. The optimal treatment regimen for Chinese NSCLC patients with EGFRex20ins and METex14 remains unclear. • This study provides a comprehensive overview of the prevalence of EGFRex20ins and METex14 mutations in the Chinese population and shows that the optimal treatment regimen for Chinese patients still remains unclear given the heterogeneity of published studies. What is the implication, and what should change now? • Further large-scale studies will be needed to improve patient management and enhance overall clinical care. The development of novel drugs will be essential to fulfill the clinical requirements. Introduction Lung cancer is a leading cause of cancer deaths worldwide. In China, it accounted for approximately 710,000 deaths in 2020, with around 80% being non-small cell lung cancers (NSCLCs) (1). NSCLC is associated with a poor 5-year survival rate, with a large proportion of patients (67.5%) having advanced disease at diagnosis (2). Over the past decades, the discovery of targetable driver mutations in NSCLC has transformed the management of patients with these mutations (3). The epidermal growth factor receptor (EGFR) gene aberrations lead to over-activation of various downstream oncogenic pathways (4), such as the phosphoinositide 3-kinase/AKT pathway. Mutations in EGFR are presented in a considerable proportion of patients with NSCLC, especially in Asian patients (30–35%) (5). There are several types of EGFR mutations, of which in-frame insertion mutations in EGFR exon 20 (EGFRexon20ins) account for 4–10%, making it the third-most frequent subtype of EGFR mutation after EGFR L858R point mutation or exon 19 deletions (6). EGFRexon20ins NSCLC has poor prognosis. It has been shown that patients carrying EGFRexon20ins have a 75% increased risk of death compared to patients who have common EGFR mutations (7). The mesenchymal-epithelial transition (MET) mutations are another group of NSCLC driver mutations. The MET proto-oncogene can be activated by MET exon 14 skipping mutation (METex14) and is also involved in cell proliferation that plays a critical role in cancer development (8). They present in approximately 3% to 4% of Western patients with NSCLC (9). However, Western NSCLC patients with METex14 mutation exhibit molecular characteristics that differ from those of Asian patients, particularly in Chinese patients as reported by previous study (10). The presence of these mutations enables the application of precision medicine through the use of targeted therapies, rather than basing treatment options on crude histological subtypes. Recently, new targeted therapies which have recently been approved include amivantamab (1) and mobocertinib (2) that target EGFRex20ins, and capmatinib (11), tepotinib (12), glumetinib (13), savolitinib (14,15), and vebreltinib (16) that target METex14 (9). Although EGFRex20ins and METex14 mutations in NSCLC have attracted considerable interest from the scientific community (5,9,17), there remains limited information on the clinical relevance and impact of these mutations in Chinese patients. Some studies investigated epidemiological and clinical burden of METex14 in lung cancer in Chinese population (9,10,18,19), but there is no systematic summary. Therefore, we conducted a scoping review to assess the currently available evidence of these two rare mutations of NSCLC in the Chinese population. The scoping review is a type of knowledge synthesis that uses a systematic and iterative approach to identify and synthesize an existing or emerging body of literature on a given topic. We present this article in accordance with the PRISMA-ScR reporting checklist (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-528/rc) (20). Methods Literature searches and identification We identified relevant studies through systematic searches of eight databases from inception to 14 November 2023: PubMed, EMBASE, The Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical (CBM), Wanfang and Chinese Scientific Journals (VIP) databases. Search terms included those related to EGFRex20ins, METex14, NSCLC and Chinese (see Appendix 1). There were no restrictions on publication language or study design. After removing duplicates, two reviewers independently determined whether articles were eligible for inclusion based on their titles and abstracts. To avoid missing studies, studies that include at least one Chinese authors also were reconfirmed in the full text to ensure the reporting of data from the Chinese population. We included studies that met the eligibility criteria, which involved examining the therapeutic effectiveness in Chinese patients with NSCLC harbouring EGFRex20ins or METex14 mutations or reporting the prevalence of EGFRex20ins or METex14 mutations in Chinese NSCLC patients, including Chinese cohorts or arms reported in multi-national studies. Case reports, reviews and abstracts were excluded. Furthermore, we were interested in examining the proportion of mutations among Chinese patients with NSCLC in the subgroup analysis such as smoking statuses and age groups. Discrepancies in data collection were resolved through discussion with a third senior author. Data extraction We extracted data from each study in a standardized manner, including information on age, gender, diagnosis, disease stage, family history, smoking status, frequency of mutations, interventions (treatment regimens, description, frequency, dosage, duration, combination of drugs), and outcomes including mutation proportion as defined by the number of NSCLC patients harboring mutation within the total number of NSCLC patients, and therapeutic effectiveness as defined by original studies such as overall survival (OS), progression-free survival (PFS), disease control rate (DCR), complete response (CR), and partial response (PR). Additional information on study design, clinical, biochemical, and pathological parameters was also collected from identified articles. If appropriate, authors of included studies were contacted to request missing or additional data. Statistical analyses Data were narratively summarized and presented in text and tables. For categorical variables, we summarized data in proportions as reported in original studies. For continuous variables, we summarized data in different outcome measures as reported in original studies using such as median OS or PFS and their 95% confidence interval (CI). Results A total of 111 studies were identified (see the list of included studies in Appendix 2), reporting on EGFRex20ins and METex14 mutations in 159,993 NSCLC Chinese patients (Figure 1). One study was based in Northeast China, 41 in Eastern China, 22 in North China, 9 in South China, 6 in Southwest China, 5 in Northwest China, and 13 in mixed regions (Figure S1). Of the 111 studies, 78 studies were single-center, 24 studies were multi-center, and this information was not available for 9 studies (Table 1). Only 8 studies were known to be funded by industry. The PRISMA flow diagram for studies included in the scoping review. NSCLC, non-small cell lung cancer. Table 1Summary of general study characteristics (total number of studies =111)Study characteristicsNumberProportion (%)Language English7567.6 Chinese3632.4Funding sources Industry87.2 Non-industry6962.2 Not-reported*2522.5 None#98.1Objectives of study Frequency of uncommon mutations10191.0 Clinical outcomes5448.6 Prognostic factors1311.7Study types (by number of centre) Single7870.3 Multi-centre2421.6 Not report98.1Number of NSCLC patients ≤1,0007971.2 >1,0003228.8*, not-reported: the study did not report any information on funding; #, none: no funding reported in the study. NSCLC, non-small cell lung cancer. Summary of general study characteristics (total number of studies =111) *, not-reported: the study did not report any information on funding; #, none: no funding reported in the study. NSCLC, non-small cell lung cancer. Of the 111 studies included, 76 studies reported on EGFRex20ins and 45 studies reported on METex14. Thirty-two studies had sample sizes of more than 1,000 patients (28.8%; Table 1). The most common method to detect the mutations was next-generation sequencing (N=35 studies), followed by reverse transcription polymerase chain reaction (RT-PCR) (N=27 studies; Table S1). Stage IV was the most reported stage (34.2%) and adenocarcinoma was the most reported subtype (52.3%) among patients with NSCLC (Table S2). Seventy-five studies were written in English, whereas 36 studies were written in Chinese (Table 1). None of the included studies reported the presence of both EGFRex20ins and METex14 mutations concurrently in NSCLC patients. However, individually these mutations have been reported to co-occur with other uncommon mutations (Table S3). EGFRex20ins Among the 76 included studies (Table S4) that reported on EGFRex20ins, the frequency of EGFRex20ins ranged from 0.02–6.56% of all NSCLC patients and 0.56–100% of all EGFR mutations in China. When we evaluated the frequency from studies with at least 1,000 patients, there were 32 studies in China; and the frequency of EGFRex20ins ranged from 0.02–2.85% of all NSCLC patients and 0.56–6.90% of all EGFR mutations (Table 2). The frequency of EGFRex20ins varied between the different regions in China, where North China reported the highest frequency and South China reported the lowest (Table S5). Table 2Frequency of EGFRex20ins & METex14 mutation for larger studies (patients n>1,000) by different regions of ChinaRegions of ChinaEGFR exon 20 insertion mutationMET exon 14 skippingNSCLCEGFR positiveNSCLCMET positiveNo. of studies% in NSCLCNo. of studies% in EGFR positiveNo. of studies% in NSCLCNo. of studies% in MET positiveNortheast China0NR0NR0NR0NREastern China110.70–2.85%81.90–6.90%20.91–1.30%NRNRNorth China12.0%13.87%10.49%18.70%Central China11.60%13.50%20.71–0.98%230.00–56.60%South China20.26–1.20%20.56–3.60%10.08%18.33%Southwest China20.64–0.70%21.44–2.46%0NR0NRNorthwest region0NR0NR0NR0NRMixed or NR40.02–2.10%43.15–5.12%40.42–1.38%112.20%Northeast China: Heilongjiang Province, Jilin Province and Liaoning Province; Eastern China: Shanghai, Jiangsu Province, Zhejiang Province, Anhui Province, Fujian Province, Jiangxi Province, Shandong Province, and Taiwan; North China: Beijing, Tianjin, Shanxi Province, Hebei Province, Inner Mongolia Autonomous Region; Central China: Henan Province, Hubei Province, Hunan Province; South China: Guangdong Province, Guangxi Zhuang Autonomous Region, Hainan Province, Hong Kong Special Administrative Region, Macao Special Administrative Region; Southwest China: Sichuan Province, Guizhou Province, Yunnan Province, Chongqing Municipality, Tibet Autonomous Region; Northwest region: Shaanxi Province, Gansu Province, Qinghai Province, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region. NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; NR, not reported. Frequency of EGFRex20ins & METex14 mutation for larger studies (patients n>1,000) by different regions of China Northeast China: Heilongjiang Province, Jilin Province and Liaoning Province; Eastern China: Shanghai, Jiangsu Province, Zhejiang Province, Anhui Province, Fujian Province, Jiangxi Province, Shandong Province, and Taiwan; North China: Beijing, Tianjin, Shanxi Province, Hebei Province, Inner Mongolia Autonomous Region; Central China: Henan Province, Hubei Province, Hunan Province; South China: Guangdong Province, Guangxi Zhuang Autonomous Region, Hainan Province, Hong Kong Special Administrative Region, Macao Special Administrative Region; Southwest China: Sichuan Province, Guizhou Province, Yunnan Province, Chongqing Municipality, Tibet Autonomous Region; Northwest region: Shaanxi Province, Gansu Province, Qinghai Province, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region. NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; NR, not reported. Twenty-eight studies reported smoking status (N=1,798 patients), in which 70.6% of patients were non-smokers (N=1,270 patients) (Table S6). Six studies perform subgroup analyses by age group (21-26). Compared to younger patients (age <60 years), the frequency of EGFRex20ins was slightly higher in older patients (age ≥60 years), with 0–14.29% versus 1.68–17.39% (Table S7). Sixteen studies evaluated the first-line treatment regimens for NSCLC patients with EGFRex20ins (Table 3). Among these studies, fourteen (N=338 patients) investigated the effectiveness of tyrosine kinase inhibitors (TKIs), with median PFS ranged from 2.0 to 9.97 months. Seven studies (N=735 patients) examined chemotherapy, with median PFS ranged from 3.4 to 15.43 months. Three studies (N=21 patients) investigated immune checkpoint therapy, with median PFS ranged from 1.7 to 2.8 months. Two studies (N=104 patients) explored the use of chemotherapy and TKI but only one study report PFS and OS. Another study (N=55 patients) explored the use of platinum and TKIs but did not report PFS or OS. Additionally, one study (N=49 patients) did not specify the examined intervention but reported a median PFS of 7.6 months (95% CI: 5.7–9.6). Table 3Summary of studies reporting the line of therapy and drug class in the target population (all in EGFRex20ins)Author, yearProspective or retrospectiveSample size (target population description)Treatments receivedCRPRSDPDORR (%)DCR (%)Median PFS (months, 95% CI)Median OS (months, 95% CI)First-line treatment EGFR TKIs Chao Shi, 2022Retrospective15–NRNRNRNRNRNR5.5 (2.537–8.463)NR Chao Shi, 2022Retrospective6 (EGFRex20ins near loopa)1st-generation EGFR TKIsNRNRNRNRNRNR3.9 (2.380–5.420)11.68 (0–24.692) Chao Shi, 2022Retrospective5 (EGFRex20ins near loopa)2nd or 3rd-generation EGFR TKIsNRNRNRNRNRNR8.9 (0–18.311)23.233 (14.029–32.438) Chihsien Huang, 2021Retrospective13AfatinibNRNRNRNRNRNR2.6NR Cheng He, 2020Retrospective1GefitinibNRNRNRNRNRNRNRNR DYL Chow, 2022Retrospective5AfatinibNRNRNRNRNRNR4.5 (0–13.2)10.4 (0.4–28.5) Guangjian Yang, 2022Retrospective16 (patients with V769_D770insASV and D770_N771insSVD mutants)–0088050.02.07 (0–6.25)NR Guangjian Yang, 2022Retrospective12 (patients with A763_Y764insFQEA and D770delinsGY mutants)–46233.383.39.97 (4.75–15.19)NR Guangjian Yang, 2022Retrospective7 (less common ex20ins subtypesb)–0034042.92.03 (0–4.86)NR Guangjian Yang, 2020Retrospective23–NRNR0NR8.78.72.9 (1.5–4.3)NR Guangjian Yang, 2020Retrospective141st-generation EGFR TKIsNRNRNRNR0NR2.0 (0.2–3.8)NR Guangjian Yang, 2020Retrospective16–NRNRNRNRNRNR2.9 (2.1–3.7)NR Guangjian Yang, 2020Retrospective7–NRNRNRNRNRNR2.0 (0.8–3.2)NR Guangjian Yang, 2020Retrospective1GefitinibNRNRNRNRNRNR3.2NR Guangjian Yang, 2020Retrospective1IcotinibNRNRNRNRNRNR1NR Huanlan Sa, 2023Retrospective19FurmonertinibNRNRNRNR26.389.5NRNR Jianchun Duan, 2023Prospective26YK-029A0195273.192.39.3 (5.85–NE)NR Jie Qian, 2022Retrospective4Afatinib0031075.02.37 (0.00–5.11)NR John Wen-Cheng Chang, 2022Retrospective32Gefitinib/erlotinib35249.425.02.3 (1.5–3.1)7.3 (0.1–16.0) John Wen-Cheng Chang, 2022Retrospective23Afatinib631426.139.12.5 (2.2–2.9)6.9 (0.1–17.2) Jennyu Wu, 2019Retrospective16TKI-containing010156.256.251.816.8 Shen Zhao, 2023Prospective52JMT101c plus afatinib/osimertinibNRNRNRNR42.3NRNRNR Ying‑Ting Liao, 2023Retrospective22–NRNRNRNR9.118.23.13 (1.03–5.4)12.4 (1.87–118.1) Yicheng Shen, 2017Retrospective2Gefitinib/erlotinib00200100NRNR Chemotherapy Chao Shi, 2022Retrospective39–NRNRNRNRNRNR9.2 (5.218–13.115)NR Chao Shi, 2022Retrospective37 (EGFRex20ins near loopa)Chemotherapy/ICIsNRNRNRNRNRNR7.2 (3.625–10.775)NR Chao Shi, 2022Retrospective27 (EGFRex20ins near loopa)–NRNRNRNRNRNR7.2 (2.611–11.789)NR Chao Shi, 2022Retrospective8 (EGFRex20ins far loopd)–NRNRNRNRNRNR15.43 (4.402–26.465)NR Chao Shi, 2022Retrospective5 (EGFRex20ins far loopd)Chemotherapy aloneNRNRNRNRNRNR15.43 (6.702–24.165)NR Chao Shi, 2022Retrospective3 (EGFRex20ins far loopd)Chemotherapy plus anti-angiogenesisNRNRNRNRNRNR6.8 (0–14.428)NR Chao Shi, 2022RetrospectiveNRChemotherapy/EGFR-TKINRNRNRNRNRNRNR14.0 (9.872–18.128) Chao Shi, 2022RetrospectiveNR (EGFRex20ins near loopa)Chemotherapy/EGFR-TKINRNRNRNRNRNRNR13.87 (7.398–20.335) Chao Shi, 2022RetrospectiveNRChemotherapy plus anti-angiogenesis/EGFR-TKI plus anti-angiogenesisNRNRNRNRNRNRNR28.7 (21.384–36.016) Chao Shi, 2022RetrospectiveNR (EGFRex20ins near loopa)Chemotherapy plus anti-angiogenesis/EGFR-TKI plus anti-angiogenesisNRNRNRNRNRNRNR26.27 (17.732–34.802) Chunwei Xu, 2020Retrospective77Pemetrexed/platinumNRNRNRNR41.5675.325.5NR Guangjian Yang, 2022Retrospective44Chemotherapy alone829718.284.15.93 (2.70–9.17)32.03 (17.55–46.52) Guangjian Yang, 2022Retrospective63Chemotherapy plus angiogenesis inhibitors2437238.196.87.73 (6.40–9.06)30.57 (19.90–41.23) Guangjian Yang, 2020Retrospective105Platinum-based chemotherapyNRNR13NR19.241.36.4 (5.7–7.1)NR Guangjian Yang, 2020Retrospective84Platinum-based chemotherapyNRNRNRNRNRNR6.5 (4.9–8.1)NR Guangjian Yang, 2020Retrospective20Platinum-based chemotherapyNRNRNRNRNRNR3.6 (0.0–8.0)NR Guangjian Yang, 2020Retrospective39Platinum-based chemotherapy with bevacizumabNRNRNRNRNRNR7.5 (5.6–9.4)NR Guangjian Yang, 2020Retrospective66Platinum-based chemotherapy without bevacizumabNRNRNRNRNRNR5.6 (2.8–8.4)NR Jiahui Zhang, 2022Retrospective31Pemetrexed and platinum-based chemotherapy plus bevacizumab01315341.990.38.3 (6.6–10.0)17.9 (8.9–26.9) Jennyu Wu, 2019Retrospective24Pemetrexed-containing0711629.2756.228 Jennyu Wu, 2019Retrospective7Taxane-containing010614.2914.293.415.9 Jennyu Wu, 2019Retrospective10Gemcitabine-containing012710303.46.3 Qingyue Lin, 2022Retrospective8Chemotherapy with/without bevacizumab034137.587.57.2 (range, 1.7–13.6)NR (range, 6.1–27.5) Ying‑Ting Liao, 2023Retrospective38Platinum-based chemotherapyNRNRNRNR26.360.55.37 (0.5–23.2)21.37 (2.77–62.5) Chemotherapy plus EGFR-TKI Yue Wang, 2020 Retrospective55–NR823323.591.2NRNR Yue Wang, 2020-3Retrospective49–NRNRNRNRNRNR7.6 (5.7–9.6)19.9 (15.9–24.0) ICIs Chao Shi, 2022Retrospective10PD-1 or single-agent PD-L1 inhibitors: 3046040100NRNRICI plus pemetrexed/platinum: 7 Chao Shi, 2022Retrospective1 (one patient with D770_P772dup)SintilimabNRNRNRNRNRNR1.7NR Chao Shi, 2022Retrospective1 (another patient with D770_P772dup)SintilimabNRNRNRNRNRNR2.5NR Guangjian Yang, 2020Retrospective5–0320601002.8NR Ying‑Ting Liao, 2023Retrospective4–0013025.02.43 (0.967–12.467)NR Chemotherapy plus ICI Guangjian Yang, 2022Retrospective15–66340.080.06.53 (5.06–8.01)Immaturee Jiahui Zhang, 2022Retrospective29–0208169.096.613.0 (11.9–14.1)22.7 (20.4–25.0) Qingyue Lin, 2022Retrospective3–012033.31006 (range, 3.8–9.9)NR (range, 12.8–28.1) Other drugs Qingyue Lin, 2022Retrospective4Amivantamab-vmjw/Sutent/vemurafenib02205010011.3 (range, 6.0–11.5)15.5 (range, 7.8–15.5)Second-line treatment EGFR TKIs Chia‑I Shen, 2022Retrospective1Erlotinib––1–––NR19.9 Cheng He, 2020Retrospective1AfatinibNRNRNRNRNRNRNRNR Guangjian Yang, 2022Retrospective13 (patients with A763_Y764insFQEA and D770delinsGY mutants)–57138.592.36.77 (5.48–8.06)NR Guangjian Yang, 2022Retrospective11 (patients without A763_Y764insFQEA and D770delinsGY mutants)–1649.163.62.23 (1.19–3.28)NR Guangjian Yang, 2020Retrospective18–NRNR1NR5.911.82.0 (1.1–2.9)NR Guangjian Yang, 2020Retrospective1AfatinibNRNRNRNRNRNR8.2NR Guangjian Yang, 2020Retrospective1ErlotinibNRNRNRNRNRNR14.3NR Huanlan Sa, 2023Retrospective25FurmonertinibNRNRNRNR40.0100.0NRNR Shen Zhao, 2023Prospective69JMT10c plus afatinib/osimertinibNRNRNRNR31.9NRNRNR Ying-Ting Liao, 2023Retrospective16–00NRNR0252.25NR Yicheng Shen, 2017Retrospective3Afatinib010233.333.3NRNR Chemotherapy Guangjian, Yang, 2020Retrospective35–NRNR15NR17.1604.0 (3.2–4.8)NR Guangjian, Yang, 2020Retrospective20Chemotherapy plus bevacizumabNRNRNRNRNRNR6.0 (4.0–8.0)NR Guangjian, Yang, 2020Retrospective15Chemotherapy aloneNRNRNRNRNRNR2.4 (1.8–3.0)NR Ying‑Ting Liao, 2023Retrospective13Platinum-based chemotherapyNRNR6NR7.753.84.73NR Ying‑Ting Liao, 2023Retrospective13Patients with single-agent chemotherapy010127.77.72.57 (range, 1.5–29.27)NR ICIs Guangjian, Yang, 2020Retrospective4–00220502.25NR Qi Gui, 2018Retrospective2–NRNRNRNRNRNRNRNR Chemotherapy plus EGFR-TKI Shen Zhao, 2023Prospective53Platinum-based chemotherapy with JMT101c and osimertinibNRNRNRNR3496.29.2 (5.5–14.3)NR Other drugs Qingyue Lin, 2022Retrospective6Amivantamab-vmjw/Sutent/vemurafenibNRNRNRNRNRNR12.3 (range, 2.0–12.3)NR (range, 2.0–21.6)Third-line treatment Chemotherapy Yenting Lin, 2017Retrospective4–0130251008.531Fourth-line treatment ICIs Guangjian Yang, 2020Retrospective1–01001001006.6NR≥1 line treatment EGFR TKIs Huanlan Sa, 2023Retrospective53Furmonertinib02029437.792.5Not reachedNR Jie Qian, 2022Retrospective7Afatinib0061063.78 (1.93–5.64)NR Jingjing Wang, 2022Retrospective4Amivantamab plus lazertinib013025.0100.0NCNC Kaiyan Chen, 2020Retrospective15–NRNRNRNR13.3NR2.623.3 Shen Zhao, 2023Prospective11 (radiological review based on independent review committee assessment)JMT101c plus afatinib 30 mg/d037127.390.9NRNR Shen Zhao, 2023Prospective6 (radiological review based on independent review committee assessment)JMT101c plus afatinib 40 mg/d024033.3100NRNR Shen Zhao, 2023Prospective12 (radiological review based on independent review committee assessment)JMT101c plus osimertinib 80 mg/d047033.391.7NRNR Shen Zhao, 2023Prospective121 (radiological review based on independent review committee assessment)JMT101c plus osimertinib 160 mg/d04273334.795NRNR Shen Zhao, 2023Prospective11 (radiological review based on investigator assessment)JMT101c plus afatinib 30 mg/d028118.290.9NRNR Shen Zhao, 2023Prospective6 (radiological review based on investigator assessment)JMT101c plus afatinib 40 mg/d024033.3100NRNR Shen Zhao, 2023Prospective12 (radiological review based on investigator assessment)JMT101c plus osimertinib 80 mg/d056041.791.7NRNR Shen Zhao, 2023Prospective121 (radiological review based on investigator assessment)JMT101c plus osimertinib 160 mg/d04471136.495NRNR EGFR-TKI plus ICI Kaiyan Chen, 2023Prospective12Sintilimab plus anlotinibNRNRNRNR41.7NR4.3NR Other drugs Jingjing Wang, 2022Retrospective3Amivantamab012033.33100.00NCNC≥3 line treatment EGFR TKIs Huanlan Sa, 2023Retrospective9FurmonertinibNRNRNRNR55.677.8NRNR ICIs Ying‑Ting Liao, 2023Retrospective3–0003002.2 (1.667–2.733)NRa, EGFR ex20ins near loop was defined as the site on the loop following the C-helix (A767–P772) of EGFR exon 20; b, less common ex20ins subtypes including P772_H773insGHP, D770_N771insGD, N771_P772insH, P772_H773insH, H773_V774insAH, and H773delinsRY; c, JMT101 is an anti-EGFR IgG1 monoclonal antibody developed using cetuximab as a prototype; d, EGFR ex20ins far loop was defined as the site on the loop following the C-helix (H773–C775) of EGFR exon 20; e, immature (at the cutoff time, the median OS of C+I (chemotherapy plus immune checkpoint inhibitor) was immature because of this treatment pattern was used in more recent times with only three events of deaths, but not for better efficacy). EGFR, epidermal growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progress free survival; CI, confidence interval; OS, overall survival; TKI, tyrosine kinase inhibitors; NR, not reported; NE, not estimable; ICIs, immune checkpoint inhibitors; NC, not calculable. Summary of studies reporting the line of therapy and drug class in the target population (all in EGFRex20ins) a, EGFR ex20ins near loop was defined as the site on the loop following the C-helix (A767–P772) of EGFR exon 20; b, less common ex20ins subtypes including P772_H773insGHP, D770_N771insGD, N771_P772insH, P772_H773insH, H773_V774insAH, and H773delinsRY; c, JMT101 is an anti-EGFR IgG1 monoclonal antibody developed using cetuximab as a prototype; d, EGFR ex20ins far loop was defined as the site on the loop following the C-helix (H773–C775) of EGFR exon 20; e, immature (at the cutoff time, the median OS of C+I (chemotherapy plus immune checkpoint inhibitor) was immature because of this treatment pattern was used in more recent times with only three events of deaths, but not for better efficacy). EGFR, epidermal growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progress free survival; CI, confidence interval; OS, overall survival; TKI, tyrosine kinase inhibitors; NR, not reported; NE, not estimable; ICIs, immune checkpoint inhibitors; NC, not calculable. Nine studies evaluated the second-line treatment regimens (Table 3). Among them, eight studies (N=159 patients in total) examined TKIs, with a median PFS ranged from 2.0 to 6.77 months. Two studies (N=83 patients in total) examined chemotherapy, reporting median PFS ranged from 2.4 to 6.0 months. Two studies (N=6 patients in total) investigated immune checkpoint therapy, with one of them reporting a median PFS of 2.3 months. One study (N=4 patients) investigated the third-line treatment, reporting a median PFS of 8.5 months. Another study (N=1 patient) investigated the fourth-line treatment, with a PFS of 6.6 months. The treatments used varied depending on the study, and there was limited evidence on whether any one treatment was superior compared to the rest in terms of clinical efficacy and safety for patients with EGFRex20ins. Patients were usually treated with EGFR TKIs and chemotherapy. Notably, the presence of EGFRex20ins was generally associated with a shorter PFS time. Eight studies involving 11,009 patients delved into prognostic factors to predict PFS or OS outcomes. Among these factors, histological type of NSCLC, patient age, and smoking status were identified as potential elements associated with PFS or OS outcomes (Table S8). Additionally, seven studies (27-33) involving 673 patients reported adverse events (AEs). Any grade AE ranged from 41.5% to 99.1%. These studies predominantly detailed grade 1–2 AEs, with common occurrences such as rash (15.4–57.3%), diarrhea (12.5–54.7%), dry skin (54.00%), decreased appetite (54.00%), and paronychia (12.0–52.00%). Moreover, three studies (27, 28, 31) documented grade 3 AEs, with incidence rates ranging from 38.0% to 62.0%. Grade ≥3 events that occurred in ≥10% of patients were rash (21.3%) and diarrhea (10.7%). MET exon 14 skipping mutation Among the 45 studies reported on METex14, the frequency of METex14 ranged from 0–26.7% of all NSCLC patients and 0–100% of all MET mutations in China (Table S9). When we evaluated the frequency from studies with at least 1,000 patients, there were 8 studies in China. The frequency of METex14 ranged from 0.08–1.38% of all NSCLC patients and 8.33–56.6% of all MET mutations (Table 2). The frequency of METex14 varied between different regions in China (Table S5), where the highest and lowest frequencies of METex14 were typically in Eastern and South China, respectively. Nineteen studies, involving 34,107 patients, reported smoking status (N=571 patients), of which 63.9% patients were non-smokers (N=365 patients) (Table S10). Nine studies perform subgroup analyses by age groups (31,34-41) (Table S11). In general, compared to younger patients (age <60 years), the frequency of METex14 was higher in older patients (age ≥60 years), with 0–4.35% versus 0.43–27.78% (Table S11). Thus far, no studies included in the scoping review evaluated treatment regimen for NSCLC patients with METex14 in China such as tepotinib and capmatinib. Eight studies evaluated first-line treatment regimens or more for NSCLC patients with METex14 (Table 4). They investigated the effectiveness of TKIs, reporting median PFS ranging from 3.4 to 11.5 months and median OS ranging from 10.9 to 35.8 months. Additionally, one study explored the use of Amivantamab, reporting a PFS of 0.8 months and OS of 0.9 months. Furthermore, three studies (14,42,43) involving 137 patients reported AEs. The incidence of AEs of any grade ranged from 36.8% to 100.0%. These studies primarily documented grade 1–2 AEs, including nausea (52.9%), edema peripheral (48.6%), rash (37.9%), decreased appetite (34.3%), vomiting (32.9%), elevated alanine aminotransferase (ALT) (28.8–36.8%), and elevated aspartate aminotransferase (AST) (20.7–28.9%), and dysgeusia (21.1%). Moreover, they reported grade 3 AEs, with incidence rates ranging from 28.0% to 45.7%. Grade ≥3 events occurring in ≥10% of patients included elevated AST (12.9%), elevated ALT (10.0%), and palmar-plantar erythrodysesthesia (PPE) (10.5%). Table 4Summary of studies reporting the line of therapy and drug class in the target population (all in METex14 skipping)Author, yearProspective or retrospectiveTarget population description (sample size)Treatments receivedCRPRSDPDORR (%)DCR (%)Median PFS (months, 95% CI)Median OS (months, 95% CI)First-line treatment MET TKIs Hanmin Wang, 2021Retrospective6Bozitinib or crizotinibNRNRNRNRNRNR418.3≥1 lines treatment MET TKIs Hanmin Wang, 2021Retrospective12Bozitinib or crizotinibNRNRNRNR33.3NR6.117.3 Hanmin Wang, 2021Retrospective5BozitinibNRNRNRNRNRNR19.623.6 Hanmin Wang, 2021Retrospective7CrizotinibNRNRNRNRNRNR1.614.2 Kang Miao 2023Retrospective17Crizotinib or savolitinib0510229.4188.2410.7 (5.2, 17.3)NR Kang Miao 2023Retrospective9SavolitinibNRNRNRNRNRNR10.1 (4.4, 19.6)NR Kang Miao 2023Retrospective8CrizotinibNRNRNRNRNRNR7.2 (3.6, 19.5)NR Shun Lu, 2022Prospective70Savolitinib33241347.181.46.9 (4.6, 8.3)12.5 (10.5, 21.4) Xingsheng Hu 2023Prospective4BPI-9016M0031075.03.4 (3.2, 3.7)NR Xiaorong Dong 2022Prospective1HS-10241––1–––4.27.7 Xinghao Ai, 2022Retrospective14Crizotinib or savolitinibNRNRNRNRNRNR11.5NR Yang Xia 2023Prospective29Ensartinib1197269936.1 (4.5, 7.8)NR Yongfeng Yu, 2022Prospective46aSavolitinib24NRNR52.2NR5.6 (4.14, 6.93)10.9 (9.2, 13.96) Yongfeng Yu, 2022Prospective13bSavolitinib12NRNR92.3NR11.0 (5.5, NC)35.8 (9.7, NC)≥2 lines treatment MET TKIs Hanmin Wang, 2021Retrospective6Bozitinib or crizotinibNRNRNRNRNRNR6.117.3Five-line treatment Other treatment Jingjing Wang, 2022Retrospective1Amivantamab–––1––0.80.9a, patients with the detectable baseline METex14 skipping; b, patients with METex14 skipping clearance post-treatment. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progress free survival; CI, confidence interval; OS, overall survival; TKI, tyrosine kinase inhibitors; NR, not reported; NC, not calculable. Summary of studies reporting the line of therapy and drug class in the target population (all in METex14 skipping) a, patients with the detectable baseline METex14 skipping; b, patients with METex14 skipping clearance post-treatment. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progress free survival; CI, confidence interval; OS, overall survival; TKI, tyrosine kinase inhibitors; NR, not reported; NC, not calculable. Discussion This scoping review consists of 111 studies that report on a total of 159,993 patients and provides the most comprehensive assessment of EGFRex20ins and METex14 mutations in Chinese NSCLC patients to date. Most of the studies were non-comparative studies. We found that the frequency of these two mutations varied between different regions in China, with the lowest frequency in the South. Forty-eight studies (76.2%) were published in the last five years since these two mutations have attracted more attention in China. Patients with these mutations were more likely to have advanced NSCLC compared to those without. The most common histological subtype was adenocarcinoma. Findings of a previous systematic review indicated that the frequency of EGFRex20ins ranged from 0.1–4% of all NSCLC patients and 1.0–12% of all EGFR mutations globally (9). In the present review, the frequency of EGFRex20ins ranged from 0.02–2.85% of all NSCLC patients and 0.56–6.90% of all EGFR mutations when we focus on the larger studies with at least 1,000 Chinese patients. The frequency of EGFRex20ins found in our study is similar to the reported data among Caucasian patients with NSCLC, although the upper range is lower in Chinese patients. The frequency of METex14 is much lower in Chinese patients (0.08–1.38%) with NSCLC than in Caucasian patients (~3%). Both mutations also account for a smaller proportion of all EGFR and MET mutations in Chinese patients with NSCLC. Therefore, the frequency of these mutations may be relatively low in Chinese patients with NSCLC. However, the frequency of these two mutations may have been underestimated since various genotyping methods were used (Table S1). Among the methodologies employed, RT-PCR, utilized in 27 studies (24.32%), was an earlier-published genotyping technique. In contrast, a more recent trend, observed in 35 studies (31.5%), involved the use of next-generation sequencing for identifying both known and novel variants (Table S1). Therefore, further large-scale studies using the next-generation sequencing are warranted to understand the frequency of these mutations in Chinese patients. The treatment regimens were assessed in NSCLC patients with EGFRex20ins mutation. The treatments used varied depending on the study, with the most common treatment regimens consisting of EGFR-specific TKIs and chemotherapy (Table 3). There was limited evidence on whether any one treatment was superior compared to the rest in terms of clinical efficacy and safety for NSCLC patients with these mutations. In general, the presence of these mutations was associated with a shorter PFS time. In recent years, emerging real-world studies are focusing on EGFR-TKIs in the treatment of EGFR-mutant NSCLC (23,44-50) in Chinese population. However, EGFR-TKIs show controversial effectiveness in EGFRex20ins. Furmonertinib has shown encouraging antitumor activity and a good safety profile in advanced NSCLC patients with EGFRex20ins and the 6-month PFS rate was 69.4% (95% CI: 53.7–85.1%) (29), whereas afatinib has not shown favorable efficacy and tolerability in the treatment of advanced lung adenocarcinomas with EGFRex20ins comparing to other EGFR mutations (23) (median PFS =2.4 months, 95% CI: 0.0–5.1 months). The similar situation was found in the treatment with Gefitinib and Erlotinib (median PFS =2.3 months, 95% CI: 1.5–3.1) (51). Moreover, the EGFR-MET bispecific antibody amivantamab showed effectiveness in the treatment of EGFRex20ins-positive NSCLC with osimertinib resistant, which is similar to the findings from other study populations (52,53). Fewer studies have examined the efficacy and effectiveness of treatments for NSCLC with METex14 mutation in the Chinese population, as indicated in Table 4. It has been shown that the median PFS was 3.4–11.5 months, and the median OS was 10.9–35.8 months in NSCLC patients with METex14 mutation who received bozitinib, savolitinib, or crizotinib treatment. In addition, the median PFS and OS were 1.9 months (95% CI: 1.9–3.7) and 10.3 months [95% CI: 7.3–not evaluable (NE)] in all 38 NSCLC patients with c-MET overexpression (n=34) or METex14 mutation (n=4) (42). The evidence on the prognostic effect of these mutations was little to assess the impact on OS time. In terms of age group and smoking status, limited evidence was available to give a clear picture for the EGFRex20ins and METex14 mutations in Chinese patients with NSCLC. There was also some evidence to assess the treatment regimens in other ethnic groups with EGFRex20ins mutation or with METex14 mutation (5). For the first-line treatment, the most common treatment regimens were chemotherapy for patients with EGFRex20ins mutation. Median OS ranged from 6.3 to 28.0 months. Median PFS and objective response rates (ORRs) were 3.4–6.9 months and 23–29%, respectively (5). For METex14 mutation, the efficacy and safety of two MET-TKIs capmatinib and tepotinib, have been previously assessed (5). These drugs yielded PFS of 5.6–12.4 months in clinical trials. However, it has been reported that one-third to half of patients showed inherent resistance to MET-TKIs. Given the evidence indicating inherent resistance to MET-TKIs in up to half of patients with METex14 mutation, future clinical trials should prioritize investigating novel therapeutic approaches or combination therapies to address this challenge. Additionally, it would be crucial to explore the efficacy and safety of these treatment regimens specifically in diverse ethnic groups to ensure a comprehensive understanding of their impact across different populations. This will not only enhance the precision of treatment but also contribute valuable insights into optimizing therapeutic strategies for patients with METex14 mutation. Our study has several strengths. We conducted systematic searches on eight databases and identified 111 studies with nearly 160,000 Chinese patients with NSCLC. The assessment of mutation frequency in larger studies should be less prone to selective reporting than in smaller studies. Furthermore, evaluation of the current literature has allowed the identification of gaps in our current knowledge, which may help direct future research in Chinese NSCLC patients. For example, there is limited evidence on which treatment option is more beneficial when considering clinical efficacy and the safety of NSCLC patients with these mutations. Additionally, the frequency of EGFRex20ins and METex14 mutations and their correlation with gender, smoking status, stage, and histological grade remains unclear, especially when considering the presence of other co-occurring genomic mutations in these patients. Limitations of our study include the possible underestimation in the frequency of EGFRex20ins and METex14 mutations in Chinese NSCLC patients, as the earlier genotyping method to detect the mutations in the included studies was RT-PCR. Mutation detection using next-generation sequencing, which focuses on large-scale studies, could potentially improve this. Further large-scale studies, including epidemiological studies and real-world data, are required to identify the association between the presence of these mutations, clinical characteristics at baseline, and treatment efficacy. Due to limited data on NSCLC patients with these mutations, we are unable to perform a meta-analysis. At present, the optimal treatment regimen for Chinese NSCLC patients with EGFRex20ins and METex14 remains unclear. In the present review, we focused on evaluating the efficacy and safety of treatment regimens for Chinese patients with EGFRex20ins or METex14 mutations, based on non-comparative studies. Among these studies, the treatment regimens of EGFRex20ins varied depending on the specific study. For NSCLC patients with MET exon 14 skipping mutations, targeted therapies such as capmatinib, tepotinib, glumetinib, savolitinib, and vebreltinib have shown efficacy and have been approved for use. In contrast, MET amplification represents a distinct alteration that may respond differently to treatment, typically requiring more comprehensive therapeutic approaches. While MET exon 14 skipping mutations directly confer sensitivity to MET inhibitors, further research is required to optimize treatment regimens, particularly for cases involving MET amplification. Conclusions Our review highlights that both EGFRex20ins and METex14 mutations account for a smaller proportion of all EGFR and MET mutations in Chinese patients with NSCLC; while several targeted therapies have been approved in China, there is still insufficient evidence regarding the optimal treatment and therapeutic efficacy for Chinese patients with NSCLC. Further large-scale studies are required to identify associations between the presence of these mutations and clinical characteristics at baseline and outcome following treatment. Supplementary The article’s supplementary files as Acknowledgments We thank Ms Yang Zhang and Dr. Zheng Ye from Systematic Review Solutions Ltd. for their assistance in methodology. Funding: This study was funded by Xi’an Janssen Pharmaceutical Ltd. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Reporting Checklist: The authors have completed the PRISMA-ScR reporting checklist. Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-528/rc Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-528/coif). All authors report that this study was funded by Xi’an Janssen Pharmaceutical Ltd. X.G. and Y.W. were employees of Xi’an Janssen Pharmaceutical Ltd. during the study. The authors have no other conflicts of interest to declare. References Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-528/prf Supplementary Materials The article’s supplementary files as